Cerebral Glucose Hypometabolism In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
| Protein Name | VIM (Vimentin) |
|---|---|
| Gene | [VIM](/proteins/vim-protein) |
| UniProt ID | [P08670](https://www.uniprot.org/uniprotkb/P08670) |
| PDB ID | 1GK4, 3KLT, 4YV3 |
| Molecular Weight | 54 kDa (466 amino acids) |
| Subcellular Localization | Cytoplasm, intermediate filaments, perinuclear region |
| Protein Family | Type III intermediate filament family |
| Brain Expression | Neurons, astrocytes, oligodendrocytes, microglia |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), Multiple Sclerosis |
Vimentin is a type III intermediate filament protein encoded by the VIM gene that serves as a key structural component of the cytoskeleton in various cell types, including neurons and glial cells. In the central nervous system, vimentin is expressed predominantly in astrocytes, microglia, and neural progenitor cells, with lower expression in mature neurons under normal conditions[1]. Vimentin plays critical roles in maintaining cellular architecture, facilitating intracellular transport, regulating signal transduction pathways, and responding to cellular stress[2].
The protein is particularly notable for its upregulation in reactive astrocytes (a process termed astrocytosis or glial scarring) in response to neurodegeneration, making it a widely used marker for assessing neuroinflammatory responses in neurodegenerative disease[3]. Beyond its structural functions, vimentin participates in numerous protein-protein interactions that regulate apoptosis, autophagy, mitochondrial dynamics, and immune responses—all processes central to neurodegeneration[4].
Vimentin exhibits the characteristic architecture of type III intermediate filament proteins:
N-terminal head domain (amino acids 1-96): Non-helical, glycine-rich region containing multiple phosphorylation sites. This domain participates in protein-protein interactions and filament assembly initiation[5].
Central rod domain (amino acids 97-410): Alpha-helical coiled-coil structure consisting of four conserved helical segments (1A, 1B, 2A, 2B) separated by linker regions (L1, L12, L2). The coiled-coil mediates dimerization and higher-order assembly[6].
C-terminal tail domain (amino acids 411-466): Variable region involved in post-translational modifications and protein interactions. Contains serine/threonine phosphorylation sites that regulate filament dynamics[7].
Vimentin assembles into a hierarchical structure:
Vimentin undergoes extensive post-translational modifications:
Vimentin provides mechanical support and maintains cellular integrity:
In astrocytes, vimentin:
During development, vimentin:
Vimentin regulates:
Vimentin pathology in AD is extensive and multifaceted:
Astrocytic Reactivity
Vimentin is dramatically upregulated in reactive astrocytes surrounding amyloid-beta plaques[10]. These vimentin-positive astrocytes exhibit:
Relationship to Neurofibrillary Tangles
Microglial Activation
Alpha-Synuclein Connection
Neuroinflammation
Astrocytic Dysfunction
Protein Aggregate Clearance
Glial Scarring
Oligodendrocyte Precursor Cells
Vimentin shows promise as a biomarker:
Reducing Vimentin Expression
Modifying Post-Translational Modifications
Blocking Vimentin Release
Several strategies are being explored:
| Partner | Interaction Type | Functional Consequence |
|---|---|---|
| GFAP | Heterodimer formation | Astrocyte IF network |
| Tau | Co-aggregation | NFT formation |
| α-Synuclein | Binding | Lewy body formation |
| TDP-43 | Co-aggregation | ALS pathology |
| Beclin-1 | Autophagy regulation | Mitophagy |
| Parkin | Mitochondrial quality control | PD pathogenesis |
The study of Cerebral Glucose Hypometabolism In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Herrmann H, et al. " (2007). Vimentin intermediate filament formation. J Mol Biol 367:297-315". 2007. ↩︎
Pekny M, et al. '(2019). Astrocytic intermediate filaments: Novel determinants of astroglial responses in neural injury and disease. Nat Neurosci 22:1075-1085'. 2019. ↩︎
Shabbir SH, et al. '(2014). Vimentin in neurodegeneration: More than just a mere marker. J Cell Physiol 229:1575-1584'. 2014. ↩︎
Eriksson JE, et al. " (2009). Vimentin as a universal marker of cellular stress. Exp Cell Res 315:1663-1672". 2009. ↩︎
Snider NT, et al. " (2011). Vimentin function in liver disease. Hepatology 53:1774-1784". 2011. ↩︎
Fuchs E, et al. '(1994). Intermediate filaments: Structure, dynamics, function, and disease. Annu Rev Cell Biol 10:113-145'. 1994. ↩︎
Inagaki M, et al. [ " (1996). Regulation of vimentin intermediate filaments in cell signaling. Trends Biochem Sci 21:319-322"](https://doi.org/10.1016/S0968-0004(96). 1996. ↩︎
Goto H, et al. " (1998). Phosphorylation of vimentin by Rho-associated kinase at a unique site. J Biol Chem 273:11728-11736". 1998. ↩︎
Tang H, et al. " (2019). Vimentin is required for mitochondrial quality control. Cell Rep 27:3228-3238". 2019. ↩︎
Kahlson MA, et al. " (2022). Reactive astrocytes as therapeutic targets in neurodegeneration. Neurotherapeutics 19:1727-1746". 2022. ↩︎
Olsson B, et al. " (2016). CSF and blood biomarkers for neurodegenerative diseases. Nat Rev Neurol 12:59-71". 2016. ↩︎